scholarly journals Correlation of a scanning laser derived oedema index and visual function following grid laser treatment for diabetic macular oedema

2003 ◽  
Vol 87 (4) ◽  
pp. 455-461 ◽  
Author(s):  
C Hudson
Keyword(s):  
Laser Treatment ◽  
Visual Function ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Scanning Laser ◽  
Grid Laser Treatment

scholarly journals Intravitreal Bevacizumab Alone Versus Combined Bevacizumab and Macular Grid Laser Photocoagulation in Diffuse Diabetic Macular Oedema

2020 ◽  
Author(s):  
Fawaz Al Sarireh ◽  
Hamzeh Mohammad Alrawashdeh ◽  
Khalid Al Zubi ◽  
Khalil Al Salem
Keyword(s):  
Visual Acuity ◽  
Laser Treatment ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Diabetic Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Systemic Complications ◽  
Prospective Longitudinal ◽  
Grid Laser Treatment ◽  
Number Of Injections

Introduction: Diabetes Mellitus (DM) is a common disease with multiple systemic complications. Diabetic macular oedema is the main threat to vision in patients with diabetic retinopathy, which results from the increased permeability of the inner and outer blood-retinal barrier. Macular argon laser photocoagulation was the only treatment of diabetic macular oedema in the past. Now-a-days, both intravitreal anti-Vascular Endothelial Growth Factor (VEGF) and macular grid laser photocoagulation are used in the management of diffuse and focal Diabetic Macular Oedema (DME). Aim: To assess the changes in both visual acuity and Central Macular Thickness (CMT) in patients with DME after intravitreal injection of bevacizumab only or in combination with macular grid laser treatment. Materials and Methods: A prospective longitudinal cohort study included 89 eyes of 52 patients with DME, who were categorised into two interventional groups. The first group received only intravitreal bevacizumab for the first three months, then Pro Re Nata (PRN), while the second group received intravitreal bevacizumab, similar to the first group, in addition to macular grid laser treatment two weeks after the initial injection. Participants were followed-up at 12 months, and the visual acuity, CMT, and the total number of injections were documented. Patients were followed-up but data was gathered on baseline and at the 12th month were compared. Results: In comparison to the initial presentation, a significant decrease in CMT was noticed in both groups (163.47±83.60 μm vs. 126.45±52.45 μm, respectively). Moreover, a significant improvement in visual acuity of both groups (p<0.023 and p<0.016, respectively) and significantly fewer injections being required in the second group were noticed. Conclusion: Combining intravitreal bevacizumab with macular grid laser treatment can lead to stabilisation and improvement of visual acuity with a smaller number of injections which was statistically significant.

Non-mydriatic ultrawide field scanning laser ophthalmoscopy compared with dilated fundal examination for assessment of diabetic retinopathy and diabetic macular oedema in Chinese individuals with diabetes mellitus

2018 ◽  
Vol 103 (9) ◽  
pp. 1327-1331 ◽  
Author(s):  
Simon K H Szeto ◽  
Raymond Wong ◽  
Jerry Lok ◽  
Fangyao Tang ◽  
Zihan Sun ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Clinical Examination ◽  
Macular Oedema ◽  
Chinese Population ◽  
Retrospective Cohort ◽  
Diabetic Macular Oedema ◽  
Scanning Laser ◽  
Scanning Laser Ophthalmoscopy ◽  
Chinese Cohort ◽  
Clinical Grading

AimsTo evaluate the performance of ultrawide field scanning laser ophthalmoscopy (UWF-SLO) for assessing diabetic retinopathy (DR) and diabetic macular oedema (DME) in a Chinese population, compared with clinical examination.MethodsThis is a retrospective cohort study. A series of 322 eyes from 164 patients with DM were included. Each patient underwent both dilated fundal examination with DR and DME grading by retina specialist and non-mydriatic 200° UWF-SLO (Daytona, Optos, Dunfermline, UK). The severity of DR and DME from UWF-SLO images was further graded by ophthalmologists, according to both international clinical DR and DME disease severity scales and the standard 7-field Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Any DR, DME and vision-threatening DR (VTDR) were treated as endpoints for this study.Results23 out of 322 images (7.14%), including all four cases with proliferative DR on clinical examinations, were determined as ungradable. When the international scale was used for grading UWF-SLO images, the sensitivity of any DR, DME and VTDR was 67.7%, 67.4% and 72.6%, respectively; the specificity of any DR, DME and VTDR was 97.8%, 97.3% and 97.8%, respectively. The agreement with clinical grading in picking up any DR, DME and VTDR was substantial, with κ-values of 0.634, 0.694 and 0.707, respectively. The performance of UWF-SLO was shown to be lower when ETDRS scale was used for grading the images.ConclusionThe performance of non-mydriatic UWF-SLO is comparable in identifying DR with that of clinical examination in a Chinese cohort. However, whether UWF-SLO can be considered as tool for screening DR is still undetermined.

Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept

2019 ◽  
Vol 29 (3) ◽  
pp. 271-277 ◽  
Author(s):  
Sergio E Hernandez-Da Mota ◽  
Enrique A Roig Melo-Granados ◽  
Jans Fromow-Guerra ◽  
Francisco Bejar-Cornejo ◽  
Roberto Gallego-Pinazo ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Regression Analysis ◽  
Correlation Analysis ◽  
Visual Function ◽  
Macular Oedema ◽  
Fundus Autofluorescence ◽  
Diabetic Macular Oedema ◽  
Optical Coherence ◽  
Average Thickness

Purpose: The aim of this study was to evaluate the correlations between fundus autofluorescence and morphologic parameters as well as visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept. Methods: A total of 34 eyes of 20 patients with untreated diabetic macular oedema received an intravitreal injection of ziv-aflibercept at baseline, and 1 and 2 months later. The baseline, 1-month, and two-month best corrected visual acuity determination, contrast sensitivity, spectral domain optical coherence tomography, mean central macular thickness, mean macular cube volume, mean macular cube average thickness, and fundus autofluorescence (decreased, normal, or increased; and single or multiple spots) were measured. Correlation analysis with a determination of Spearman’s rank correlation coefficient, regression analysis, agreement between investigators, and Friedman’s test were used for statistical analyses. Results: A direct correlation was observed between baseline fundus autofluorescence and macular cube average thickness at 1 month (r = 0.51, p = 0.020) and between fundus autofluorescence at 1 month and baseline macular cube average thickness (r = 0.50, p = 0.021). Regression analysis showed a coefficient of determination of 0.29 (p = 0.016) between baseline fundus autofluorescence and macular cube average thickness at 1 month. Conclusion: In patients with diabetic macular oedema, the pretreatment baseline degree of foveal fundus autofluorescence might be helpful in predicting macular cube average thickness in patients undergoing treatment with intravitreal ziv-aflibercept in the short term.

Visual Function and Structure Outcomes in a Patient with Diabetic Macular Oedema Insufficiently Responsive to Available Therapies – Treatment with Fluocinolone Acetonide Implant

2014 ◽  
Vol 08 (02) ◽  
pp. 137
Author(s):  
Érica ABC Guerreiro Paulo ◽  
Claus Eckardt ◽  
◽  
Keyword(s):  
Visual Function ◽  
Macular Oedema ◽  
Therapeutic Option ◽  
Diabetic Macular Oedema ◽  
Fluocinolone Acetonide ◽  
Eye Drops ◽  
Short Term ◽  
Patient Reported ◽  
Before And After ◽  
Insufficient Response

Importance:Early experience with intraocular, non-biodegradable fluocinolone acetonide (FAc) (0.2 μg/day) implant (ILUVIEN®), comparing visual function before and after treatment in an insufficiently responsive diabetic macular oedema (DMO) patient.Observations:This 62-yearold male patient with type 2 diabetes mellitus was first treated for DMO in 2004, when best corrected visual acuity (BCVA) was 0.8 for his right eye. He did not visit an ophthalmologist again until 2011 when BCVA had declined to 0.2. Three separate, monthly intravitreal (IV) ranibizumab injections and additional laser photocoagulation resulted in no improvement. Subsequently, 0.7 mg IV dexamethasone was administered, giving short-term DMO improvement. However, six further IV ranibizumab injections produced no effect and a combined injection of IV ranibizumab with 0.7 mg IV dexamethasone provided only short-term improvements. Following phacoemulsification, a 0.2 μg/day FAc implant was administered. Optical coherence tomography (OCT) indicated complete DMO regression after 3 weeks, sustained 6 months post-implant. BCVA improved to 0.25 and the patient reported greater vision-related quality of life. Intraocular pressure increased gradually but resolved with daily timolol/dorzolamide and tafluoprost eye drops.Conclusions and relevance:In a DMO patient showing insufficient response to IV ranibizumab and dexamethasone injections, FAc implant provided an effective therapeutic option with manageable side effects.

scholarly journals Visual acuity and perimetry as measures of visual function in diabetic macular oedema

Diabetologia ◽  
2005 ◽  
Vol 49 (1) ◽  
pp. 200-206 ◽  
Author(s):  
E. Agardh ◽  
H. Stjernquist ◽  
A. Heijl ◽  
B. Bengtsson
Keyword(s):  
Visual Acuity ◽  
Visual Function ◽  
Macular Oedema ◽  
Diabetic Macular Oedema

scholarly journals Scanning laser ophthalmoscopy in the retromode in diabetic macular oedema

2012 ◽  
Vol 90 (5) ◽  
pp. e374-e380 ◽  
Author(s):  
Stela Vujosevic ◽  
Barbara Trento ◽  
Elisa Bottega ◽  
Francesca Urban ◽  
Elisabetta Pilotto ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Scanning Laser ◽  
Scanning Laser Ophthalmoscopy
Sign in / Sign up

Export Citation Format

Share Document